Do analysts rate BNR or SBC?

SBC Medical Group has a consensus target price of $8.50, indicating a potential upside of 175.97%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SBC Medical Group 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer BNR or LFMD?

LifeMD has a consensus target price of $9.14, suggesting a potential upside of 122.13%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Do analysts prefer BNR or BDSX?

Biodesix has a consensus price target of $28.33, indicating a potential upside of 25.65%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts recommend BNR or XGN?

Exagen has a consensus price target of $9.11, indicating a potential upside of 95.94%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Do analysts rate PARK or BNR?

Park Dental Partners currently has a consensus price target of $21.75, suggesting a potential upside of 0.93%. Given Park Dental Partners' stronger consensus rating and higher possible upside, equities research analysts plainly believe Park Dental Partners is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PARK or BNR?

Park Dental Partners has higher revenue and earnings than Burning Rock Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Park Dental Partners $244.49M 0.40 -$360K N/A N/A Burning Rock Biotech $77.16M 1.14 -$7.92M -$0.82 N/A

Burning Rock Biotech (BNR) Competitors

$8.37 +0.29 (+3.59%)

Closing price 06/30/2026 03:59 PM Eastern

Extended Trading

$8.60 +0.24 (+2.81%)

As of 06/30/2026 06:51 PM Eastern

Compare

BNR vs. SBC, LFMD, BDSX, XGN, and PARK

Should you buy Burning Rock Biotech stock or one of its competitors? MarketBeat compares Burning Rock Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Burning Rock Biotech include SBC Medical Group (SBC), LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), and Park Dental Partners (PARK). These companies are all part of the "healthcare" industry.

How does Burning Rock Biotech compare to SBC Medical Group?

Burning Rock Biotech (NASDAQ:BNR) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SBC Medical Group has a net margin of 24.09% compared to Burning Rock Biotech's net margin of -11.57%. SBC Medical Group's return on equity of 15.90% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
SBC Medical Group	24.09%	15.90%	11.61%

SBC Medical Group has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.14	-$7.92M	-$0.82	N/A
SBC Medical Group	$173.61M	1.82	$50.99M	$0.39	7.90

SBC Medical Group has a consensus target price of $8.50, indicating a potential upside of 175.97%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Burning Rock Biotech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

In the previous week, Burning Rock Biotech and Burning Rock Biotech both had 1 articles in the media. Burning Rock Biotech's average media sentiment score of 1.89 equaled SBC Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
SBC Medical Group	Very Positive

Summary

SBC Medical Group beats Burning Rock Biotech on 13 of the 14 factors compared between the two stocks.

How does Burning Rock Biotech compare to LifeMD?

Burning Rock Biotech (NASDAQ:BNR) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, LifeMD had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat LifeMD's score of 0.62 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
LifeMD	Positive

Burning Rock Biotech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LifeMD has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.14	-$7.92M	-$0.82	N/A
LifeMD	$194.05M	1.03	$14.35M	$0.05	82.32

LifeMD has a consensus target price of $9.14, suggesting a potential upside of 122.13%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has a net margin of 2.37% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
LifeMD	2.37%	-150.88%	-22.59%

Summary

LifeMD beats Burning Rock Biotech on 11 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Biodesix?

Burning Rock Biotech (NASDAQ:BNR) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Burning Rock Biotech has a net margin of -11.57% compared to Biodesix's net margin of -33.26%. Burning Rock Biotech's return on equity of -10.98% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Biodesix	-33.26%	-2,101.40%	-35.65%

In the previous week, Biodesix had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Biodesix and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Biodesix's score of 1.79 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Biodesix	Very Positive

Burning Rock Biotech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Burning Rock Biotech has higher earnings, but lower revenue than Biodesix. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.14	-$7.92M	-$0.82	N/A
Biodesix	$88.50M	2.64	-$35.26M	-$4.06	N/A

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biodesix has a consensus price target of $28.33, indicating a potential upside of 25.65%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Burning Rock Biotech beats Biodesix on 9 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Exagen?

Burning Rock Biotech (NASDAQ:BNR) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Burning Rock Biotech has higher revenue and earnings than Exagen. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.14	-$7.92M	-$0.82	N/A
Exagen	$66.57M	1.69	-$19.95M	-$0.89	N/A

Burning Rock Biotech has a net margin of -11.57% compared to Exagen's net margin of -29.49%. Burning Rock Biotech's return on equity of -10.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Exagen	-29.49%	-94.37%	-28.96%

In the previous week, Exagen had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Burning Rock Biotech. Exagen's average media sentiment score of 1.93 beat Burning Rock Biotech's score of 1.89 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Exagen	Very Positive

Burning Rock Biotech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Exagen has a consensus price target of $9.11, indicating a potential upside of 95.94%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Exagen beats Burning Rock Biotech on 10 of the 17 factors compared between the two stocks.

How does Burning Rock Biotech compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Park Dental Partners had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Park Dental Partners and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Park Dental Partners' score of 1.12 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Park Dental Partners	Positive
Burning Rock Biotech	Very Positive

30.0% of Burning Rock Biotech shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Park Dental Partners has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Park Dental Partners' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Park Dental Partners currently has a consensus price target of $21.75, suggesting a potential upside of 0.93%. Given Park Dental Partners' stronger consensus rating and higher possible upside, equities research analysts plainly believe Park Dental Partners is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Park Dental Partners has higher revenue and earnings than Burning Rock Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.40	-$360K	N/A	N/A
Burning Rock Biotech	$77.16M	1.14	-$7.92M	-$0.82	N/A

Summary

Park Dental Partners beats Burning Rock Biotech on 9 of the 13 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$84.99M	$4.22B	$6.83B	$12.45B
Dividend Yield	N/A	2.09%	3.16%	6.16%
P/E Ratio	-10.21	42.43	30.26	24.87
Price / Sales	1.14	47.80	364.40	102.84
Price / Cash	N/A	37.05	23.56	58.59
Price / Book	1.15	4.75	5.89	6.54
Net Income	-$7.92M	$31.79M	$203.69M	$336.70M
7 Day Performance	-1.76%	0.90%	0.86%	2.88%
1 Month Performance	-4.12%	-10.15%	-4.57%	0.64%
1 Year Performance	161.56%	21.52%	26.62%	31.34%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	1.1455 of 5 stars	$8.37 +3.6%	N/A	+164.0%	$84.99M	$77.16M	N/A	1,390	Positive News Gap Up
SBC SBC Medical Group	4.1622 of 5 stars	$3.07 +4.1%	$8.50 +176.9%	-33.6%	$302.60M	$169.34M	7.87	N/A
LFMD LifeMD	2.6892 of 5 stars	$4.55 +5.6%	$9.14 +100.9%	-69.8%	$208.45M	$193.33M	91.02	230
BDSX Biodesix	4.1616 of 5 stars	$19.16 +10.4%	$26.50 +38.3%	+299.5%	$179.68M	$96.10M	N/A	220	Positive News
XGN Exagen	4.3133 of 5 stars	$4.36 -1.4%	$9.25 +112.2%	-33.4%	$106.79M	$66.57M	N/A	220	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. SBC, LFMD, BDSX, XGN, and PARK

How does Burning Rock Biotech compare to SBC Medical Group?

Summary

How does Burning Rock Biotech compare to LifeMD?

Summary

How does Burning Rock Biotech compare to Biodesix?

Summary

How does Burning Rock Biotech compare to Exagen?

Summary

How does Burning Rock Biotech compare to Park Dental Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. SBC, LFMD, BDSX, XGN, and PARK

How does Burning Rock Biotech compare to SBC Medical Group?

Do institutionals & insiders hold more shares of BNR or SBC?

Is BNR or SBC more profitable?

Which has better valuation & earnings, BNR or SBC?

Do analysts rate BNR or SBC?

Which has more risk and volatility, BNR or SBC?

Does the media favor BNR or SBC?

Summary

How does Burning Rock Biotech compare to LifeMD?

Does the media favor BNR or LFMD?

Which has more volatility & risk, BNR or LFMD?

Do institutionals and insiders have more ownership in BNR or LFMD?

Which has stronger earnings & valuation, BNR or LFMD?

Do analysts prefer BNR or LFMD?

Is BNR or LFMD more profitable?

Summary

How does Burning Rock Biotech compare to Biodesix?

Is BNR or BDSX more profitable?

Does the media favor BNR or BDSX?

Which has more volatility and risk, BNR or BDSX?

Which has higher earnings & valuation, BNR or BDSX?

Do institutionals & insiders hold more shares of BNR or BDSX?

Do analysts prefer BNR or BDSX?

Summary

How does Burning Rock Biotech compare to Exagen?

Which has higher valuation and earnings, BNR or XGN?

Is BNR or XGN more profitable?

Does the media favor BNR or XGN?

Which has more risk and volatility, BNR or XGN?

Do analysts recommend BNR or XGN?

Do institutionals and insiders hold more shares of BNR or XGN?

Summary

How does Burning Rock Biotech compare to Park Dental Partners?

Does the media prefer PARK or BNR?

Do insiders & institutionals hold more shares of PARK or BNR?

Is PARK or BNR more profitable?

Do analysts rate PARK or BNR?

Which has higher valuation and earnings, PARK or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools